Biotechnology company Genentech, part of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that it has secured US Food and Drug Administration (FDA) approval for its Vabysmo (faricimab-svoa) prefilled syringe for treating three retinal conditions that can cause blindness.
The Vabysmo 6.0 mg single-dose prefilled syringe (PFS) is indicated for use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect almost three million people in the United States.
Designed to simplify administration, Vabysmo PFS offers retina specialists a ready-to-use option. It delivers the same medication as existing Vabysmo vials.
Vabysmo has already gained approval in over 95 countries for wet AMD and DME, with RVO approvals in selected regions.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA